Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,991.86 (-0.85%)
DOW   34,061.69 (-0.83%)
QQQ   284.81 (-0.74%)
AAPL   145.23 (-1.94%)
MSFT   242.96 (-1.83%)
META   109.30 (-1.89%)
GOOGL   96.33 (-1.16%)
AMZN   94.52 (+1.19%)
TSLA   187.20 (+2.37%)
NVDA   160.95 (-1.08%)
NIO   10.34 (+1.67%)
BABA   76.29 (+1.05%)
AMD   73.76 (-1.84%)
T   18.84 (-1.46%)
MU   56.38 (-3.48%)
CGC   3.48 (-4.92%)
F   13.77 (-2.20%)
GE   86.76 (-1.57%)
DIS   96.32 (-2.58%)
AMC   7.29 (-2.93%)
PYPL   80.71 (+0.79%)
PFE   49.40 (+0.39%)
NFLX   283.67 (-0.65%)
S&P 500   3,991.86 (-0.85%)
DOW   34,061.69 (-0.83%)
QQQ   284.81 (-0.74%)
AAPL   145.23 (-1.94%)
MSFT   242.96 (-1.83%)
META   109.30 (-1.89%)
GOOGL   96.33 (-1.16%)
AMZN   94.52 (+1.19%)
TSLA   187.20 (+2.37%)
NVDA   160.95 (-1.08%)
NIO   10.34 (+1.67%)
BABA   76.29 (+1.05%)
AMD   73.76 (-1.84%)
T   18.84 (-1.46%)
MU   56.38 (-3.48%)
CGC   3.48 (-4.92%)
F   13.77 (-2.20%)
GE   86.76 (-1.57%)
DIS   96.32 (-2.58%)
AMC   7.29 (-2.93%)
PYPL   80.71 (+0.79%)
PFE   49.40 (+0.39%)
NFLX   283.67 (-0.65%)
S&P 500   3,991.86 (-0.85%)
DOW   34,061.69 (-0.83%)
QQQ   284.81 (-0.74%)
AAPL   145.23 (-1.94%)
MSFT   242.96 (-1.83%)
META   109.30 (-1.89%)
GOOGL   96.33 (-1.16%)
AMZN   94.52 (+1.19%)
TSLA   187.20 (+2.37%)
NVDA   160.95 (-1.08%)
NIO   10.34 (+1.67%)
BABA   76.29 (+1.05%)
AMD   73.76 (-1.84%)
T   18.84 (-1.46%)
MU   56.38 (-3.48%)
CGC   3.48 (-4.92%)
F   13.77 (-2.20%)
GE   86.76 (-1.57%)
DIS   96.32 (-2.58%)
AMC   7.29 (-2.93%)
PYPL   80.71 (+0.79%)
PFE   49.40 (+0.39%)
NFLX   283.67 (-0.65%)
S&P 500   3,991.86 (-0.85%)
DOW   34,061.69 (-0.83%)
QQQ   284.81 (-0.74%)
AAPL   145.23 (-1.94%)
MSFT   242.96 (-1.83%)
META   109.30 (-1.89%)
GOOGL   96.33 (-1.16%)
AMZN   94.52 (+1.19%)
TSLA   187.20 (+2.37%)
NVDA   160.95 (-1.08%)
NIO   10.34 (+1.67%)
BABA   76.29 (+1.05%)
AMD   73.76 (-1.84%)
T   18.84 (-1.46%)
MU   56.38 (-3.48%)
CGC   3.48 (-4.92%)
F   13.77 (-2.20%)
GE   86.76 (-1.57%)
DIS   96.32 (-2.58%)
AMC   7.29 (-2.93%)
PYPL   80.71 (+0.79%)
PFE   49.40 (+0.39%)
NFLX   283.67 (-0.65%)
NASDAQ:NUVA

NuVasive - NUVA Stock Forecast, Price & News

$37.73
-0.35 (-0.92%)
(As of 11/28/2022 12:24 PM ET)
Add
Compare
Today's Range
$37.30
$38.14
50-Day Range
$35.68
$46.45
52-Week Range
$35.17
$60.47
Volume
10,470 shs
Average Volume
593,466 shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.62

NuVasive MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
36.8% Upside
$51.62 Price Target
Short Interest
Healthy
3.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of NuVasive in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.27%
From $2.04 to $2.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

345th out of 1,040 stocks

Surgical & Medical Instruments Industry

40th out of 103 stocks

NUVA stock logo

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock News Headlines

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
NuVasive Third Quarter 2022 Earnings: Misses Expectations
NuVasive Announces Third Quarter 2022 Financial Results
NuVasive (NUVA) Surpasses Q3 Earnings Estimates
NuVasive to Sponsor and Participate at EUROSPINE 2022
Where NuVasive Stands With Analysts
NuVasive Announces Agenda for Investor Day 2022
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings
11/09/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
2,900
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$51.62
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$44.00
Forecasted Upside/Downside
+36.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-64,090,000.00
Pretax Margin
-1.13%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.71 per share
Book Value
$15.37 per share

Miscellaneous

Free Float
51,889,000
Market Cap
$1.97 billion
Optionable
Optionable
Beta
1.06

Social Links


Key Executives

  • Mr. J. Christopher BarryMr. J. Christopher Barry (Age 48)
    CEO & Director
    Comp: $2.93M
  • Mr. Matthew K. Harbaugh (Age 52)
    Exec. VP & CFO
    Comp: $939.39k
  • Mr. Dale A. Wolf (Age 42)
    Sr. VP of Global Operations
    Comp: $679.16k
  • Mr. Nathaniel B. Sisitsky Esq. (Age 47)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $787.93k
  • Mr. Marc Rosenbaum (Age 50)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Ryan Donahoe
    Sr. VP & Chief Technology Officer
  • Mr. Johnson Lai
    Chief Information Officer
  • Ms. Juliet C. Cunningham
    VP of Investor Relations
  • Mr. Michael Farrington
    Sr. VP of People & Culture
  • Mr. Sean Freeman
    Sr. VP of Strategy & Corp. Devel.













NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price forecast for 2023?

9 Wall Street research analysts have issued twelve-month price targets for NuVasive's stock. Their NUVA share price forecasts range from $44.00 to $63.00. On average, they predict the company's stock price to reach $51.62 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How have NUVA shares performed in 2022?

NuVasive's stock was trading at $52.48 at the beginning of the year. Since then, NUVA stock has decreased by 27.4% and is now trading at $38.08.
View the best growth stocks for 2022 here
.

When is NuVasive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NUVA earnings forecast
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Wednesday, November, 9th. The medical device company reported $0.54 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.54. The medical device company earned $295.30 million during the quarter, compared to analysts' expectations of $298.76 million. NuVasive had a negative net margin of 1.70% and a positive trailing twelve-month return on equity of 12.49%. NuVasive's quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS.

How will NuVasive's stock buyback program work?

NuVasive declared that its board has authorized a stock buyback program on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY22 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $2.00-2.10 for the period, compared to the consensus earnings per share estimate of $2.24. The company issued revenue guidance of ~$1.2-1.213 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.38%), Thrivent Financial for Lutherans (4.93%), Macquarie Group Ltd. (4.47%), Dimensional Fund Advisors LP (2.58%), Channing Capital Management LLC (2.40%) and Stephens Investment Management Group LLC (1.53%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends
.

How do I buy shares of NuVasive?

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $38.08.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $1.99 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does NuVasive have?

The company employs 2,900 workers across the globe.

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 11/28/2022 by MarketBeat.com Staff